Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
OncoCyte Corporation OCX
$0.25
-$0.02 (-6.92%)
На 18:00, 12 мая 2023
+312.00%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
32193402.00000000
-
week52high
1.35
-
week52low
0.20
-
Revenue
958000
-
P/E TTM
-1
-
Beta
1.62006900
-
EPS
-0.17000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 12:30
Описание компании
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Overweight | Overweight | 18 авг 2022 г. |
| Needham | Buy | Buy | 11 авг 2022 г. |
| Lake Street | Buy | Buy | 11 авг 2022 г. |
| Stephens & Co. | Equal-Weight | Overweight | 24 мая 2022 г. |
| Piper Sandler | Overweight | Overweight | 16 мая 2022 г. |
| Piper Sandler | Overweight | Overweight | 14 ноя 2022 г. |
| Needham | Buy | Buy | 11 ноя 2022 г. |
| Piper Sandler | Neutral | Overweight | 18 ноя 2022 г. |
| Lake Street | Hold | Buy | 01 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Riggs Josh | A | 257485 | 257485 | 17 янв 2023 г. |
| John Anish M. | A | 250466 | 250466 | 17 янв 2023 г. |
| Liu James Yang | A | 57065 | 57065 | 17 янв 2023 г. |
| Gutfreund John Peter | A | 75000 | 75000 | 23 дек 2022 г. |
| Arno Andrew | A | 532049 | 250000 | 23 дек 2022 г. |
| KINGSLEY ALFRED D | A | 439111 | 25000 | 22 дек 2022 г. |
| Ross Douglas T. | A | 234114 | 213797 | 21 дек 2022 г. |
| Paulsen Gisela | D | 0 | 125000 | 16 дек 2022 г. |
| Paulsen Gisela | D | 54687 | 70313 | 16 дек 2022 г. |
| Paulsen Gisela | D | 203125 | 171875 | 16 дек 2022 г. |
Новостная лента
Oncocyte To Announce First Quarter 2023 Financial Results
GlobeNewsWire
27 апр 2023 г. в 16:59
IRVINE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it will release its first quarter 2023 financial results on Thursday, May 11, 2023, before U.S. market open.
Broadwood Partners Now Owns 33.3% of OncoCyte
24/7 Wall Street
10 апр 2023 г. в 22:23
Fintel reports that Broadwood Partners has filed a 13D/A form with the SEC disclosing ownership of 57.13MM shares of OncoCyte Corp (OCX).
Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call
GlobeNewsWire
29 мар 2023 г. в 16:01
IRVINE, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it has changed the date of its previously announced earnings conference call. It will now report its fourth quarter and full year 2022 financial results on Monday, April 3, 2023. In conjunction with the release, Oncocyte will host a conference call and webcast that day at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. The company plans to file its Annual Report on Form 10-K on Friday, March 31, 2023.
3 Medical Services Stocks to Buy Amid Industry Challenges
Zacks Investment Research
10 мар 2023 г. в 12:15
The Zacks Medical - Services industry is growing on digital healthcare adoption. EMBC, INNV and OCX are set to gain the most.
Oncocyte cuts 40% of staff
Market Watch
16 дек 2022 г. в 08:19
Oncocyte Corp. shares rose 5% in premarket trades after the Irvine, Calif., molecular diagnostics company for the detection of cancer, said it would reduce more than 40% of its workforce "to align its team towards key products that address larger markets.